Loading
Alzheimer S Disease / Tauopathies / Neurodegenerative Disease · Observational Study
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registry record describing a planned observational study of [18F]NIDF, a novel tau-targeting PET imaging tracer, in neurodegenerative disease. The study is actively recruiting and has not yet reported results; it aims to characterize safety and biodistribution in approximately 20 participants. No efficacy, diagnostic accuracy, or outcome data are available from this registry entry.
Observational. Neurodegenerative Disease, Alzheimer s Disease, Tauopathies; age from 18 Years; to 90 Years; accepts healthy volunteers. Intervention: Healthy participants; Patients with cognitive impairment. n = 20. 3 sites: China.
This is a clinical trial registry record describing a planned observational study of [18F]NIDF, a novel tau-targeting PET imaging tracer, in neurodegenerative disease. The study is actively recruiting and has not yet reported results; it aims to characterize safety and biodistribution in approximately 20 participants. No efficacy, diagnostic accuracy, or outcome data are available from this registry entry.
This is a registry record with no results posted; no efficacy, safety outcomes, or diagnostic accuracy data are reported.
This is preliminary feasibility and safety work on a new tau-PET tracer. Clinicians should await completion and peer-reviewed publication of results before any diagnostic or clinical use; the study is not yet powered for clinical validation.
This is an active registry record for an observational feasibility study of a novel tau-PET tracer with no results yet posted; it describes planned safety and biodistribution assessment in 20 participants.
As stated by the source record.
Quoted from the source exactly as published.
This is preliminary feasibility and safety work on a new tau-PET tracer. Clinicians should await completion and peer-reviewed publication of results before any diagnostic or clinical use; the study is not yet powered for clinical validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07306598). This is a study registration, not published results. Lead sponsor: Tianjin Medical University. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 20 participants (ESTIMATED). Conditions: Neurodegenerative Disease, Alzheimer s Disease, Tauopathies. Primary outcome measures: Safety Assessment , From time of injection up to 7 days post-injection; The Biodistribution of [18F]NIDF in subjects , At the time of the single [18F]FT8 PET/CT scan (Day 1). Brief summary: In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents. This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F\]NIDF PET imaging. \[18F\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific/off-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F\]NIDF PET imaging in human subjects.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.